[go: up one dir, main page]

WO2004064728A3 - Use of specific tetracycline compounds in therapy - Google Patents

Use of specific tetracycline compounds in therapy Download PDF

Info

Publication number
WO2004064728A3
WO2004064728A3 PCT/US2004/001036 US2004001036W WO2004064728A3 WO 2004064728 A3 WO2004064728 A3 WO 2004064728A3 US 2004001036 W US2004001036 W US 2004001036W WO 2004064728 A3 WO2004064728 A3 WO 2004064728A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
tetracycline compounds
specific tetracycline
specific
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/001036
Other languages
French (fr)
Other versions
WO2004064728A2 (en
Inventor
Stuart B Levy
Michael Draper
Mark L Nelson
Graham Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Publication of WO2004064728A2 publication Critical patent/WO2004064728A2/en
Publication of WO2004064728A3 publication Critical patent/WO2004064728A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.
PCT/US2004/001036 2003-01-16 2004-01-16 Use of specific tetracycline compounds in therapy Ceased WO2004064728A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44114103P 2003-01-16 2003-01-16
US60/441,141 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004064728A2 WO2004064728A2 (en) 2004-08-05
WO2004064728A3 true WO2004064728A3 (en) 2004-12-16

Family

ID=32771908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001036 Ceased WO2004064728A2 (en) 2003-01-16 2004-01-16 Use of specific tetracycline compounds in therapy

Country Status (1)

Country Link
WO (1) WO2004064728A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250331A1 (en) * 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
JP4416652B2 (en) 2002-07-12 2010-02-17 パラテック ファーマシューティカルズ インコーポレイテッド 3, 10 and 12a substituted tetracycline compounds
WO2005070878A1 (en) * 2004-01-15 2005-08-04 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
SI1753713T1 (en) * 2004-05-21 2017-01-31 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP1778252A4 (en) * 2004-08-11 2010-01-27 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
US8466132B2 (en) * 2004-10-25 2013-06-18 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2005299294B2 (en) * 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
AU2006214543A1 (en) * 2005-02-15 2006-08-24 Wyeth 9-substituted tetracyclines
EP1910273A2 (en) * 2005-07-21 2008-04-16 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
KR20080041722A (en) * 2005-08-31 2008-05-13 와이어쓰 9-aminocarbonyl substituted derivatives of glycylcycline
CN100516067C (en) * 2006-01-10 2009-07-22 上海恒瑞医药有限公司 Taxol derivatives with antitumor activity
CA2648668C (en) 2006-04-07 2015-06-23 The President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
US7763735B2 (en) 2006-10-11 2010-07-27 President And Fellows Of Harvard College Synthesis of enone intermediate
EP2455367B1 (en) * 2006-12-21 2015-12-16 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
PL2120963T3 (en) * 2006-12-21 2019-05-31 Paratek Pharm Innc Substituted tetracycline compounds for treatment of inflammatory skin disorders
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
PT2271348T (en) * 2008-03-28 2018-04-16 Paratek Pharm Innc FORMULATION OF ORAL TETRACYCIN COMPOUND TABLET
EP2307027A4 (en) 2008-07-11 2012-08-15 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
AU2009292986A1 (en) * 2008-09-19 2010-03-25 Paratek Pharmaceuticals, Inc. Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
EP2424834B1 (en) 2009-04-30 2018-07-11 President and Fellows of Harvard College Synthesis of tetracyclines and intermediates thereof
US20120329761A1 (en) * 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
CN102204921B (en) * 2011-04-14 2012-12-26 苏州大学 Application of tetracycline derivative in preparing sensitizing drug for radiotherapy
CN103717571B8 (en) * 2011-07-26 2017-05-17 山东亨利医药科技有限责任公司 9-aminomethyl substituted tetracycline compound
CN104797429B (en) 2012-11-21 2017-04-19 日本曹达株式会社 Recording material, recording sheet using non-phenolic compound, and method of using non-phenolic compound for color developer
CN103142624A (en) * 2013-03-01 2013-06-12 西南大学 Application of antibiotic tigecycline in preparing anti-cancer medicine
KR102237887B1 (en) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. Methods of treating infections in overweight and obese patients using antibiotics
JP6783777B2 (en) * 2015-02-09 2020-11-11 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． How to prevent secondary infections
US10633337B2 (en) * 2016-06-22 2020-04-28 Kbp Biosciences Co., Ltd. Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof
WO2019241490A1 (en) * 2018-06-13 2019-12-19 Texas Tech University System Novel modified tetracyclines for treatment of alcohol use disorder, pain and other disorder involving potential inflammatory processes
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
WO2022079204A1 (en) 2020-10-14 2022-04-21 Institut Du Cerveau Et De La Moelle Epiniere Tetracycline derivatives for treating neurodegenerative or neuroinflammatory diseases
BR112023015520A2 (en) * 2021-02-03 2023-10-24 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet CHEMICALLY COUPLED CARRIER FOR BIOACTIVE DRUGS WITH LOW HYDROPHOBICITY IN THE CENTRAL NERVOUS SYSTEM
EP4551552A1 (en) 2022-07-08 2025-05-14 ICM (Institut du Cerveau et de la Moelle Épinière) Tetracycline derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052575A1 (en) * 1997-05-20 1998-11-26 The Trustees Of Columbia University In The City Of New York Use of metalloproteinase inhibitors in the treatment and prevention of pulmonary emphysema
WO2000016783A1 (en) * 1998-09-21 2000-03-30 The Research Foundation Of State University Of New York Method of preventing acute lung injury
WO2001062261A1 (en) * 2000-02-25 2001-08-30 Arakis Ltd. Metalloproteinase inhibitors for the treatment of respiratory diseases
WO2002072031A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
WO2002072022A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
WO2003061767A1 (en) * 2002-01-25 2003-07-31 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052575A1 (en) * 1997-05-20 1998-11-26 The Trustees Of Columbia University In The City Of New York Use of metalloproteinase inhibitors in the treatment and prevention of pulmonary emphysema
WO2000016783A1 (en) * 1998-09-21 2000-03-30 The Research Foundation Of State University Of New York Method of preventing acute lung injury
WO2001062261A1 (en) * 2000-02-25 2001-08-30 Arakis Ltd. Metalloproteinase inhibitors for the treatment of respiratory diseases
WO2002072031A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
WO2002072022A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
WO2003061767A1 (en) * 2002-01-25 2003-07-31 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders

Also Published As

Publication number Publication date
WO2004064728A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004064728A3 (en) Use of specific tetracycline compounds in therapy
WO2003005971A3 (en) Tetracycline compounds having target therapeutic activities
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2005097119A3 (en) Pten inhibitors
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003300200A1 (en) Valve treatment catheter and methods
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
EP1636160A4 (en) Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
AU2003299378A1 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
IL166016A0 (en) Topical treatment of skin diseases
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
AU2003240545A1 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2003274649A1 (en) Diagnostic markers for therapeutic treatment
AU2003297570A1 (en) Treatment of skin diseases
WO2004093919A3 (en) Target for cancer therapy and drug discovery
AU2003247810A1 (en) Novel therapeutic target for treating vascular diseases, dyslipidemias and related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase